• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthBrainstorm Health

Brainstorm Health: Keytruda Lung Cancer Trial, Virtual PT, Novartis Gene Therapy Deal

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
April 9, 2018, 3:31 PM ET

Happy Monday, readers! I hope you had a great weekend. This is Sy.

Digital tech is slowly but surely creeping into the medical sphere. Just consider the ways in which patients are clamoring for more telemedicine and virtual doctor visit options while medical schools are harnessing virtual reality systems like Microsoft’s Hololens to teach anatomy to young surgeons. Now, a new study suggests that virtual physical therapy (PT) may be more effective and cheaper than the old-school variety.

The research was conducted by Cleveland Clinic scientists, centered on technology developed by Reflexion Health, and was published in the Journal of Knee Surgery (since, well, it featured patients going through PT after hip or knee surgeries).

Reflexion’s Virtual Exercise Rehabilitation Assistant (VERA) system is meant to help patients stick to the physical therapy regimens that can help them recover from those kinds of serious surgical procedures. According to the (admittedly small) initial study, which examined 157 knee surgery patients, it was a success, with 80% of the participants sticking with the home PT regimens prescribed by their physicians. Reflexion says that rate usually hovers much lower at somewhere between 35% and 70% (although those numbers are based on self-reported patient surveys, which can be unreliable).

But the data pulled from the study is still striking. “Patients in the study spent an average of approximately 27 minutes per day exercising over the course of an average 30 days in recovery,” wrote the researchers. The combination of the VERA platform and telemedicine visits—important to people who aren’t at full physical capacity—reportedly “resulted in associated savings in time, steps, and money for patients, providers, and payers.”

Read on for the day’s news.

Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

DIGITAL HEALTH

Could Medicare cover seniors' Uber tab to the hospital? Forbes contributor Bruce Jaspen has an intriguing piece out on the ways that recent moves by the federal government may allow Medicare Advantage, the private component of the massive government health care program for seniors and disabled Americans, to pay for "supplemental services" like trips to the hospital—which could prove a boon for ride-sharing service like Uber and Lyft, which are already making significant moves into the medical transportation business. The agency that runs Medicare announced last week that it was "reinterpreting the standards for health-related supplemental benefits in the Medicare Advantage program to include additional services that increase health and improve quality of life"—criteria which could possibly include hospital rides for the sick, disabled, and elderly. (Forbes)

INDICATIONS

Merck stock soars on Keytruda's triumph over chemo. Shares of drug giant Merck spiked more than 6% (!) in Monday trading. That's a massive upswing for a company with well over $140 billion in market value. The reason for the rise? The continuing domination of Merck's flagship cancer immunotherapy drug Keytruda, which may soon be able to be prescribed as a go-to, first-line treatment for lung cancer (the second most diagnosed cancer in America and by far the deadliest) without the need for chemotherapy at all if newly reported study results hold steady. (Fortune)

Novartis snaps up gene therapy upstart AveXis for $8.7 billion. Fresh Novartis CEO Vas Narasimhan has made the first major acquisition of his still-young tenure leading the Swiss pharmaceutical giant: The company is buying AxeVis, a gene therapy-focused biotech, in a deal valued at $8.7 billion. What's more, AxeVis is working in a critical and hugely difficult therapeutic space—spinal muscular atrophy (SMA), an inherited and degenerative muscle-wasting disease. Narasimhan has previously stated his interest in precision medicine and rare diseases (I'll be speaking with him this afternoon, so more on this soon). (Fortune)

THE BIG PICTURE

California considers a radical health care price control bill. Single payer health care is all the rage in certain sections of the left-wing political arena. But a new bill proposed in California would be equally ambitious in scope (and bring up a lot of the same sharp criticisms)—but without that headline-catching name and with an important difference in approach. The bill would set up an "all payer rate setting" system. This is one that strives for many of the same goals as single payer; but rather than have that eponymous "single payer" (i.e., the government or government-backed entity), the system of private insurance and hospitals would remain, albeit with some major changes. For instance, these firms would all be subject to price controls based on the rates that Medicare pays for various health care services. The bill is backed heavily by labor unions and consumer advocacy groups; doctors' organizations and hospitals are warning that it would lead to care rationing and a loss of access to medical services. (Los Angeles Times)

REQUIRED READING

20 Advocacy Groups Say YouTube Illegally Collects Data on Kids, by Hallie Detrick

Commentary: How These Useless Doctors' Exams Are Raising Health Care Costs, by Niran Al-Agba & Meg Edison

Why Apple Co-Founder Steve Wozniak Joined the #DeleteFacebook Movement, by David Meyer

Predicting Success for Mark Zuckerberg's Trip to Washington, D.C., by Adam Lashinsky

Produced by Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

Find past coverage. Sign up for other Fortune newsletters.
About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

boomer
CommentaryLongevity
America is not ready for its own longevity crisis — and 2026 is the wake-up call
By Aimee DeCamillo and Diane TyApril 12, 2026
21 hours ago
dalmation
AIHealth
Man’s best friend may soon live a little longer thanks to a new pill promising to extend your pup’s lifespan
By Catherina GioinoApril 11, 2026
2 days ago
AI promises to free workers from grunt work, but psychologists say those mindless tasks are exactly what our brains need to recover
AIworker productivity
AI promises to free workers from grunt work, but psychologists say those mindless tasks are exactly what our brains need to recover
By Marco Quiroz-GutierrezApril 11, 2026
2 days ago
Alpha Brain Review
HealthDietary Supplements
Alpha Brain Review (2026): Expert Reviewed Nootropic
By Emily PharesApril 10, 2026
2 days ago
The 5 Best Weight Loss Pills of 2026: Expert and Doctor Approved
HealthDietary Supplements
The 5 Best Weight Loss Pills of 2026: Expert and Doctor Approved
By Emily PharesApril 10, 2026
3 days ago
Ritual Synbiotic+ Probiotic Review (2026): An Expert’s Opinion
HealthDietary Supplements
Ritual Synbiotic+ Probiotic Review (2026): An Expert’s Opinion
By Christina SnyderApril 10, 2026
3 days ago

Most Popular

'This is the last warning.' Iran threatens U.S. warships after they throw down the gauntlet for winner-take-all Strait of Hormuz
Politics
'This is the last warning.' Iran threatens U.S. warships after they throw down the gauntlet for winner-take-all Strait of Hormuz
By Fortune EditorsApril 11, 2026
1 day ago
'People are trying to be creative': Tariff-battered American companies are so cash-starved they are using refund claims as collateral for loans
Economy
'People are trying to be creative': Tariff-battered American companies are so cash-starved they are using refund claims as collateral for loans
By Fortune EditorsApril 12, 2026
24 hours ago
A 93-year-old refused to sell her home to the Masters golf course that’s spent $280 million on expansion: ‘Money ain’t everything’
Real Estate
A 93-year-old refused to sell her home to the Masters golf course that’s spent $280 million on expansion: ‘Money ain’t everything’
By Fortune EditorsApril 12, 2026
20 hours ago
The 'affordability economy' has created a housing market nobody predicted: Prices collapsing in the Sun Belt, soaring in the Rust Belt
Real Estate
The 'affordability economy' has created a housing market nobody predicted: Prices collapsing in the Sun Belt, soaring in the Rust Belt
By Fortune EditorsApril 11, 2026
2 days ago
Here's how a U.S. naval blockade of the Strait of Hormuz could work. 'This is a big task, and it's a big gamble'
Politics
Here's how a U.S. naval blockade of the Strait of Hormuz could work. 'This is a big task, and it's a big gamble'
By Fortune EditorsApril 12, 2026
15 hours ago
Palantir CEO says AI ‘will destroy’ humanities jobs but there will be ‘more than enough jobs’ for people with vocational training
Future of Work
Palantir CEO says AI ‘will destroy’ humanities jobs but there will be ‘more than enough jobs’ for people with vocational training
By Fortune EditorsApril 11, 2026
2 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.